The announcement of a substantial cash and cash equivalents position can be seen as a positive indicator of financial stability for NeuroBo Pharmaceuticals. This could potentially reassure investors about the company's ability to fund operations and invest in growth, which might lead to a short-term positive impact on the stock price.